A Randomized, Open-Label, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Nilotinib Versus Imatinib In Adult Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST)

Patients with GIST will be randomized to receive either Nilotinib or Imatinib